Parnesh Raniga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Parnesh Raniga has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Jurgen Fripp
Australian eHealth Research Centre, Commonwealth Scientific and Industrial Research Organisation, Herston, Australia
14 shared publications - Pierrick Bourgeat
CSIRO Health and Biosecurity, Australian E‐Health Research Centre, Brisbane, QLD Australia
14 shared publications - Olivier Salvado
School of Electrical Engineering and Robotics, Queensland University of Technology
12 shared publications Victor L. Villemagne
The University of Melbourne, Parkville, Australia
9 shared publications- Oscar Acosta
Université Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000 Rennes, France
8 shared publications Christopher C. Rowe
The Florey Institute of Neuroscience and Mental Health Melbourne Australia
7 shared publications
Latest Publications
- 27 September 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e207-e208
TH24. INVESTIGATION OF THE CAUSAL RELATIONSHIP BETWEEN IRON ACCUMULATION IN THE BRAIN AND NEURODEGENERATIVE DISEASE
- 27 September 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e207-e208
TH24. INVESTIGATION OF THE CAUSAL RELATIONSHIP BETWEEN IRON ACCUMULATION IN THE BRAIN AND NEURODEGENERATIVE DISEASE
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Amyloid angiopathy may contribute to white‐matter hyperintensities in Alzheimer’s disease
Background: Cerebral amyloid angiopathy (CAA) is characterised by the accumulation of amyloid‐b (Aβ) in cerebral vessels and is often coexistent with Alzheimer’s disease (AD). However, the overlap between CAA and AD and the contribution of CAA pathology to cerebrovascular lesions are not well understood. We hypothesize that in subjects with high Aβ load, the presence of imaging markers of CAA would be associated with greater white matter hyperintensities (WMH) burden.Method: Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL). See www.aibl.csiro.au. We analysed MRI (SWI and FLAIR) and 11C‐PiB‐PET data from 98 cognitively normal (CN), 34 mild‐cognitive impairment (MCI) and 38 AD participants. Subjects were classified as being Aβ+ if their Aβ load was above 20 centiloid.SWI images were manually read for lobar microbleeds (LMB) and superficial siderosis. Subjects were classified as probable‐CAA (PCAA, 2 or more LMB or siderosis), possible‐CAA (SCAA, single LMB or siderosis) or non‐CAA (NCAA) based on the modified Boston criteria. Subjects classified as SCAA (n = 24) were excluded from further analysis since literature shows this group to be heterogenous and having low incidence of CAA pathology. WMH were automatically quantified on FLAIR. Group comparisons of WMH load were made using Kruskal Wallis rank test. A GLM was performed comparing WMH (log10 transformed) and CAA/ Aβ+ classification with age, intracranial volume, gender, APOE‐ε4 genotype and use of anti‐platelet or anticoagulant medication modelled as covariates.Result: Significantly higher WMH volume was observed in PCAA (n = 17) than NCAA (n = 129) (p‐value = 0.021, d = 0.36). When amyloid status was considered, PCAA/Aβ+ (n = 15) subjects had a significantly higher WMH load than NCAA/Aβ+ (n = 57) subjects (p‐value = 0.012, d = 0.57) and NCAA/Aβ‐ (n = 72) subjects (p‐value = 0.0006, d = 0.76) (Figure 1). PCAA/Aβ‐ (n = 2) were removed from further analysis. GLM results showed a significant association of WMH with PCAA/Aβ+ as compared to NCAA/Aβ+ (p‐value = 0.02, beta = 0.322 [0.056,0.588]).Conclusion: Our findings suggest that CAA may contribute to WMH burden in subjects with high Aβ load. Further studies are required to validate our observations and characterise the contributions of CAA compared to small vessel disease associated with traditional risk factors towards the phenotype of AD.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Amyloid angiopathy may contribute to white‐matter hyperintensities in Alzheimer’s disease
Background: Cerebral amyloid angiopathy (CAA) is characterised by the accumulation of amyloid‐b (Aβ) in cerebral vessels and is often coexistent with Alzheimer’s disease (AD). However, the overlap between CAA and AD and the contribution of CAA pathology to cerebrovascular lesions are not well understood. We hypothesize that in subjects with high Aβ load, the presence of imaging markers of CAA would be associated with greater white matter hyperintensities (WMH) burden.Method: Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL). See www.aibl.csiro.au. We analysed MRI (SWI and FLAIR) and 11C‐PiB‐PET data from 98 cognitively normal (CN), 34 mild‐cognitive impairment (MCI) and 38 AD participants. Subjects were classified as being Aβ+ if their Aβ load was above 20 centiloid.SWI images were manually read for lobar microbleeds (LMB) and superficial siderosis. Subjects were classified as probable‐CAA (PCAA, 2 or more LMB or siderosis), possible‐CAA (SCAA, single LMB or siderosis) or non‐CAA (NCAA) based on the modified Boston criteria. Subjects classified as SCAA (n = 24) were excluded from further analysis since literature shows this group to be heterogenous and having low incidence of CAA pathology. WMH were automatically quantified on FLAIR. Group comparisons of WMH load were made using Kruskal Wallis rank test. A GLM was performed comparing WMH (log10 transformed) and CAA/ Aβ+ classification with age, intracranial volume, gender, APOE‐ε4 genotype and use of anti‐platelet or anticoagulant medication modelled as covariates.Result: Significantly higher WMH volume was observed in PCAA (n = 17) than NCAA (n = 129) (p‐value = 0.021, d = 0.36). When amyloid status was considered, PCAA/Aβ+ (n = 15) subjects had a significantly higher WMH load than NCAA/Aβ+ (n = 57) subjects (p‐value = 0.012, d = 0.57) and NCAA/Aβ‐ (n = 72) subjects (p‐value = 0.0006, d = 0.76) (Figure 1). PCAA/Aβ‐ (n = 2) were removed from further analysis. GLM results showed a significant association of WMH with PCAA/Aβ+ as compared to NCAA/Aβ+ (p‐value = 0.02, beta = 0.322 [0.056,0.588]).Conclusion: Our findings suggest that CAA may contribute to WMH burden in subjects with high Aβ load. Further studies are required to validate our observations and characterise the contributions of CAA compared to small vessel disease associated with traditional risk factors towards the phenotype of AD.
- 1 April 2017
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 97-100
A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping
Quantitative medical imaging often utilizes intensity normalization based on a signal from a neighboring region. The choice of this region can substantially affect the quantification, and is potentially confounded by the presence of pathology or other limitations such as partial volume effect. In this paper we outline the desirable list of criteria for selecting a normalization region of interest, and utilize this approach for quantitative susceptibility mapping (QSM) MRI in a study of neurodegeneration. The proposed criteria includes (i) association between reference region and demographics such as age, (ii) diagnostic group separation effect in the reference region, (iii) correlation between reference and target regions, (iv) local variance in the reference region, and (v) reduced cross-sectional variance within the diagnostic groups using the reference region. The intensity normalization was then evaluated using 119 subjects with normal cognition, mild cognitive impairment and Alzheimer's disease. For QSM applications in ageing we found that normalizing by the white matter regions not only satisfies the criteria but it also provides the best separation between clinical groups in the brain nuclei regions.
- 1 April 2017
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 97-100
A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping
Quantitative medical imaging often utilizes intensity normalization based on a signal from a neighboring region. The choice of this region can substantially affect the quantification, and is potentially confounded by the presence of pathology or other limitations such as partial volume effect. In this paper we outline the desirable list of criteria for selecting a normalization region of interest, and utilize this approach for quantitative susceptibility mapping (QSM) MRI in a study of neurodegeneration. The proposed criteria includes (i) association between reference region and demographics such as age, (ii) diagnostic group separation effect in the reference region, (iii) correlation between reference and target regions, (iv) local variance in the reference region, and (v) reduced cross-sectional variance within the diagnostic groups using the reference region. The intensity normalization was then evaluated using 119 subjects with normal cognition, mild cognitive impairment and Alzheimer's disease. For QSM applications in ageing we found that normalizing by the white matter regions not only satisfies the criteria but it also provides the best separation between clinical groups in the brain nuclei regions.
- Open Access
Resting state functional coupling between the ascending synchronising system, limbic system and the default mode network via theta oscillations
In order to better understand dysfunction in dementia and psychiatric illnesses, the underlying neuronal systems that give rise to normal memory and cognitive processes need to be better understood. Based on electrophysiological recordings in animals, theta oscillations have been proposed as an intrinsic mechanism for the orchestration of memory functions, especially episodic and autobiographical memory. Theta oscillations are controlled by the ascending synchronising system, a set of nucleui in the pontine tegmentum and basal forebrain. At a network level, the default mode network has been shown to be responsible for episodic and autobiographical. Using resting state fMRI data, we show using an ICA approach, seed based connectivity and dynamic causal modelling that the ascending synchronising system is coupled to the medial temporal lobe nodes including the hippocampus and parahippocampal gyrus and with the default mode network. Our results provide thus support the role of theta oscillations in memory function and coordination at a network level. Highlights: Resting state functional coupling between the DMN, MTL and ascending synchronising system. Theta oscillations may be the basis of this coupling given the role of these structures in control of theta. Theta oscillations have been implicated in memory, cognition and predictive coding. DMN, MTL and ASS are implicated in Alzheimer’s disease. Abbreviations: MRI Magnetic resonance imaging fMRI functional magnetic resonance imaging rs-fmri resting state functional magnetic resonance imaging PnO Pontine nucleus oralis SuM Supra-mamillary nucleus. MS Medial septum DB Diagonal band of Broca. VTA ventral tegmental area PCC Posterior cingulate cortex HC Hippocampus ARAS Ascending reticular activating system ASS Ascending synchronising system DMN Default Mode Network aMPFC Anterior Medial Prefrontal Cortex pIPL Posterior inferior parietal lobule NBM Nucleus Basalis Mynert DCM Dynamic causal modelling PHG Parahippocampal Gyrus
Open AccessResting state functional coupling between the ascending synchronising system, limbic system and the default mode network via theta oscillations
In order to better understand dysfunction in dementia and psychiatric illnesses, the underlying neuronal systems that give rise to normal memory and cognitive processes need to be better understood. Based on electrophysiological recordings in animals, theta oscillations have been proposed as an intrinsic mechanism for the orchestration of memory functions, especially episodic and autobiographical memory. Theta oscillations are controlled by the ascending synchronising system, a set of nucleui in the pontine tegmentum and basal forebrain. At a network level, the default mode network has been shown to be responsible for episodic and autobiographical. Using resting state fMRI data, we show using an ICA approach, seed based connectivity and dynamic causal modelling that the ascending synchronising system is coupled to the medial temporal lobe nodes including the hippocampus and parahippocampal gyrus and with the default mode network. Our results provide thus support the role of theta oscillations in memory function and coordination at a network level. Highlights: Resting state functional coupling between the DMN, MTL and ascending synchronising system. Theta oscillations may be the basis of this coupling given the role of these structures in control of theta. Theta oscillations have been implicated in memory, cognition and predictive coding. DMN, MTL and ASS are implicated in Alzheimer’s disease. Abbreviations: MRI Magnetic resonance imaging fMRI functional magnetic resonance imaging rs-fmri resting state functional magnetic resonance imaging PnO Pontine nucleus oralis SuM Supra-mamillary nucleus. MS Medial septum DB Diagonal band of Broca. VTA ventral tegmental area PCC Posterior cingulate cortex HC Hippocampus ARAS Ascending reticular activating system ASS Ascending synchronising system DMN Default Mode Network aMPFC Anterior Medial Prefrontal Cortex pIPL Posterior inferior parietal lobule NBM Nucleus Basalis Mynert DCM Dynamic causal modelling PHG Parahippocampal Gyrus
- Open Access
- 24 September 2016
- Published by SAGE Publications in International Journal of Stroke
- Vol. 12 (1) , 108-113
ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly
Cerebral microbleeds seen on brain magnetic resonance imaging are markers of small vessel disease, linked to cognitive dysfunction and increased ischemic and hemorrhagic stroke risk. Observational studies suggest that aspirin use may induce cerebral microbleeds, and associated overt intracranial hemorrhage, but this has not been definitively resolved. ASPREE-NEURO will determine the effect of aspirin on cerebral microbleed development over three years in healthy adults aged 70 years and over, participating in the larger ‘ASPirin in Reducing Events in the Elderly (ASPREE)’ primary prevention study of aspirin. Five hundred and fifty-nine participants provide 75% power (two-sided p value of 0.05) to determine an average difference of 0.5 cerebral microbleed per person after three years. A multi-center, randomized placebo-controlled trial of 100 mg daily aspirin in participants who have brain magnetic resonance imaging at study entry, one and three years after randomization and who undergo cognitive testing at the same time points. The primary outcome is the number of new cerebral microbleeds on magnetic resonance imaging after three years. Secondary outcomes are the number of new cerebral microbleeds after one year, change in volume of white matter hyperintensity, cognitive function, and stroke. ASPREE-NEURO will resolve whether aspirin affects the presence and number of cerebral microbleeds, their relationship with cognitive performance, and indicate whether consideration of cerebral microbleeds alters the risk-benefit profile of aspirin in primary prevention for older people. Australian New Zealand Clinical Trials Registry ACTRN12613001313729.
- 24 September 2016
- Published by SAGE Publications in International Journal of Stroke
- Vol. 12 (1) , 108-113
Open AccessASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly
Cerebral microbleeds seen on brain magnetic resonance imaging are markers of small vessel disease, linked to cognitive dysfunction and increased ischemic and hemorrhagic stroke risk. Observational studies suggest that aspirin use may induce cerebral microbleeds, and associated overt intracranial hemorrhage, but this has not been definitively resolved. ASPREE-NEURO will determine the effect of aspirin on cerebral microbleed development over three years in healthy adults aged 70 years and over, participating in the larger ‘ASPirin in Reducing Events in the Elderly (ASPREE)’ primary prevention study of aspirin. Five hundred and fifty-nine participants provide 75% power (two-sided p value of 0.05) to determine an average difference of 0.5 cerebral microbleed per person after three years. A multi-center, randomized placebo-controlled trial of 100 mg daily aspirin in participants who have brain magnetic resonance imaging at study entry, one and three years after randomization and who undergo cognitive testing at the same time points. The primary outcome is the number of new cerebral microbleeds on magnetic resonance imaging after three years. Secondary outcomes are the number of new cerebral microbleeds after one year, change in volume of white matter hyperintensity, cognitive function, and stroke. ASPREE-NEURO will resolve whether aspirin affects the presence and number of cerebral microbleeds, their relationship with cognitive performance, and indicate whether consideration of cerebral microbleeds alters the risk-benefit profile of aspirin in primary prevention for older people. Australian New Zealand Clinical Trials Registry ACTRN12613001313729.
- 24 March 2016
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 87 (11) , 1261-1263
Tissue atrophy and elevated iron concentration in the extrapyramidal motor system in Friedreich ataxia: the IMAGE-FRDA study
In the brain, accumulation or redistribution of iron within, and atrophy of, the cerebellar dentate nuclei have been reported.1–3 The dentate nuclei are iron-laden structures pivotal to movement coordination. However, basal ganglia and midbrain structures also have high iron content, express high levels of frataxin, and play key roles in motor regulation. Furthermore, the dentate nuclei directly innervate the thalamus and red nuclei, and indirectly project to the striatum. This biology motivates the hypothesis that iron-related pathology and/or degeneration within these extrapyramidal stations may also feature in FRDA. To test this hypothesis, we analysed tissue volume and iron concentration within the dentate nuclei, midbrain (red nuclei, substantia nigra), basal ganglia (caudate, putamen and pallidum), and thalami in individuals with FRDA and healthy controls using magnetic resonance imaging (MRI).
- 24 March 2016
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 87 (11) , 1261-1263
Tissue atrophy and elevated iron concentration in the extrapyramidal motor system in Friedreich ataxia: the IMAGE-FRDA study
In the brain, accumulation or redistribution of iron within, and atrophy of, the cerebellar dentate nuclei have been reported.1–3 The dentate nuclei are iron-laden structures pivotal to movement coordination. However, basal ganglia and midbrain structures also have high iron content, express high levels of frataxin, and play key roles in motor regulation. Furthermore, the dentate nuclei directly innervate the thalamus and red nuclei, and indirectly project to the striatum. This biology motivates the hypothesis that iron-related pathology and/or degeneration within these extrapyramidal stations may also feature in FRDA. To test this hypothesis, we analysed tissue volume and iron concentration within the dentate nuclei, midbrain (red nuclei, substantia nigra), basal ganglia (caudate, putamen and pallidum), and thalami in individuals with FRDA and healthy controls using magnetic resonance imaging (MRI).
- Open Access
- 24 February 2015
- Published by Springer Nature in Health Information Science and Systems
- Vol. 3 (S1) , S6
Design, implementation and operation of a multimodality research imaging informatics repository
Background: Biomedical imaging research increasingly involves acquiring, managing and processing large amounts of distributed imaging data. Integrated systems that combine data, meta-data and workflows are crucial for realising the opportunities presented by advances in imaging facilities. Methods: This paper describes the design, implementation and operation of a multi-modality research imaging data management system that manages imaging data obtained from biomedical imaging scanners operated at Monash Biomedical Imaging (MBI), Monash University in Melbourne, Australia. In addition to Digital Imaging and Communications in Medicine (DICOM) images, raw data and non-DICOM biomedical data can be archived and distributed by the system. Imaging data are annotated with meta-data according to a study-centric data model and, therefore, scientific users can find, download and process data easily. Results: The research imaging data management system ensures long-term usability, integrity inter-operability and integration of large imaging data. Research users can securely browse and download stored images and data, and upload processed data via subject-oriented informatics frameworks including the Distributed and Reflective Informatics System (DaRIS), and the Extensible Neuroimaging Archive Toolkit (XNAT).
- 24 February 2015
- Published by Springer Nature in Health Information Science and Systems
- Vol. 3 (S1) , S6
Open AccessDesign, implementation and operation of a multimodality research imaging informatics repository
Background: Biomedical imaging research increasingly involves acquiring, managing and processing large amounts of distributed imaging data. Integrated systems that combine data, meta-data and workflows are crucial for realising the opportunities presented by advances in imaging facilities. Methods: This paper describes the design, implementation and operation of a multi-modality research imaging data management system that manages imaging data obtained from biomedical imaging scanners operated at Monash Biomedical Imaging (MBI), Monash University in Melbourne, Australia. In addition to Digital Imaging and Communications in Medicine (DICOM) images, raw data and non-DICOM biomedical data can be archived and distributed by the system. Imaging data are annotated with meta-data according to a study-centric data model and, therefore, scientific users can find, download and process data easily. Results: The research imaging data management system ensures long-term usability, integrity inter-operability and integration of large imaging data. Research users can securely browse and download stored images and data, and upload processed data via subject-oriented informatics frameworks including the Distributed and Reflective Informatics System (DaRIS), and the Extensible Neuroimaging Archive Toolkit (XNAT).
- Open Access
- 27 March 2014
- Published by Frontiers Media SA in Frontiers in Neuroinformatics
- Vol. 8, 30
The multi-modal Australian ScienceS Imaging and Visualization Environment (MASSIVE) high performance computing infrastructure: applications in neuroscience and neuroinformatics research
The Multi-modal Australian ScienceS Imaging and Visualisation Environment (MASSIVE) is a national imaging and visualisation facility established by Monash University, the Australian Synchrotron, the Commonwealth Scientific Industrial Research Organisation (CSIRO), and the Victorian Partnership for Advanced Computing (VPAC), with funding from the National Computational Infrastructure and the Victorian Government. The MASSIVE facility provides hardware, software and expertise to drive research in the biomedical sciences, particularly advanced brain imaging research using synchrotron x-ray and infrared imaging, functional and structural magnetic resonance imaging (MRI), x-ray computer tomography (CT), electron microscopy and optical microscopy. The development of MASSIVE has been based on best practice in system integration methodologies, frameworks, and architectures. The facility has: (i) integrated multiple different neuroimaging analysis software components, (ii) enabled cross-platform and cross-modality integration of neuroinformatics tools, and (iii) brought together neuroimaging databases and analysis workflows. MASSIVE is now operational as a nationally distributed and integrated facility for neuroinfomatics and brain imaging research.
- 27 March 2014
- Published by Frontiers Media SA in Frontiers in Neuroinformatics
- Vol. 8, 30
Open AccessThe multi-modal Australian ScienceS Imaging and Visualization Environment (MASSIVE) high performance computing infrastructure: applications in neuroscience and neuroinformatics research
The Multi-modal Australian ScienceS Imaging and Visualisation Environment (MASSIVE) is a national imaging and visualisation facility established by Monash University, the Australian Synchrotron, the Commonwealth Scientific Industrial Research Organisation (CSIRO), and the Victorian Partnership for Advanced Computing (VPAC), with funding from the National Computational Infrastructure and the Victorian Government. The MASSIVE facility provides hardware, software and expertise to drive research in the biomedical sciences, particularly advanced brain imaging research using synchrotron x-ray and infrared imaging, functional and structural magnetic resonance imaging (MRI), x-ray computer tomography (CT), electron microscopy and optical microscopy. The development of MASSIVE has been based on best practice in system integration methodologies, frameworks, and architectures. The facility has: (i) integrated multiple different neuroimaging analysis software components, (ii) enabled cross-platform and cross-modality integration of neuroinformatics tools, and (iii) brought together neuroimaging databases and analysis workflows. MASSIVE is now operational as a nationally distributed and integrated facility for neuroinfomatics and brain imaging research.
- Open Access
- 10 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e84777
MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET
β-amyloid (Aβ) plaques in brain's grey matter (GM) are one of the pathological hallmarks of Alzheimer's disease (AD), and can be imaged in vivo using Positron Emission Tomography (PET) with 11C or 18F radiotracers. Estimating Aβ burden in cortical GM has been shown to improve diagnosis and monitoring of AD. However, lacking structural information in PET images requires such assessments to be performed with anatomical MRI scans, which may not be available at different clinical settings or being contraindicated for particular reasons. This study aimed to develop an MR-less Aβ imaging quantification method that requires only PET images for reliable Aβ burden estimations. The proposed method has been developed using a multi-atlas based approach on 11C-PiB scans from 143 subjects (75 PiB+ and 68 PiB- subjects) in AIBL study. A subset of 20 subjects (PET and MRI) were used as atlases: 1) MRI images were co-registered with tissue segmentation; 2) 3D surface at the GM-WM interfacing was extracted and registered to a canonical space; 3) Mean PiB retention within GM was estimated and mapped to the surface. For other participants, each atlas PET image (and surface) was registered to the subject's PET image for PiB estimation within GM. The results are combined by subject-specific atlas selection and Bayesian fusion to generate estimated surface values. All PiB+ subjects (N = 75) were highly correlated between the MR-dependent and the PET-only methods with Intraclass Correlation (ICC) of 0.94, and an average relative difference error of 13% (or 0.23 SUVR) per surface vertex. All PiB- subjects (N = 68) revealed visually akin patterns with a relative difference error of 16% (or 0.19 SUVR) per surface vertex. The demonstrated accuracy suggests that the proposed method could be an effective clinical inspection tool for Aβ imaging scans when MRI images are unavailable.
- 10 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e84777
Open AccessMR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET
β-amyloid (Aβ) plaques in brain's grey matter (GM) are one of the pathological hallmarks of Alzheimer's disease (AD), and can be imaged in vivo using Positron Emission Tomography (PET) with 11C or 18F radiotracers. Estimating Aβ burden in cortical GM has been shown to improve diagnosis and monitoring of AD. However, lacking structural information in PET images requires such assessments to be performed with anatomical MRI scans, which may not be available at different clinical settings or being contraindicated for particular reasons. This study aimed to develop an MR-less Aβ imaging quantification method that requires only PET images for reliable Aβ burden estimations. The proposed method has been developed using a multi-atlas based approach on 11C-PiB scans from 143 subjects (75 PiB+ and 68 PiB- subjects) in AIBL study. A subset of 20 subjects (PET and MRI) were used as atlases: 1) MRI images were co-registered with tissue segmentation; 2) 3D surface at the GM-WM interfacing was extracted and registered to a canonical space; 3) Mean PiB retention within GM was estimated and mapped to the surface. For other participants, each atlas PET image (and surface) was registered to the subject's PET image for PiB estimation within GM. The results are combined by subject-specific atlas selection and Bayesian fusion to generate estimated surface values. All PiB+ subjects (N = 75) were highly correlated between the MR-dependent and the PET-only methods with Intraclass Correlation (ICC) of 0.94, and an average relative difference error of 13% (or 0.23 SUVR) per surface vertex. All PiB- subjects (N = 68) revealed visually akin patterns with a relative difference error of 16% (or 0.19 SUVR) per surface vertex. The demonstrated accuracy suggests that the proposed method could be an effective clinical inspection tool for Aβ imaging scans when MRI images are unavailable.